Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1621 | FS120 Wiki | 0.38 |
| drug1745 | GNX102 Wiki | 0.38 |
| drug1177 | Corticosteroids and Derivatives Wiki | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug241 | AeroEclipse II Breath Actuated Nebulizer Wiki | 0.38 |
| drug2665 | Monalizumab Wiki | 0.38 |
| drug1412 | EHR-based Clinician Jumpstart Wiki | 0.38 |
| drug441 | Avdoralimab Wiki | 0.38 |
| drug451 | Azacytidine Wiki | 0.38 |
| drug601 | Bintrafusp alfa Wiki | 0.38 |
| drug439 | Autophagy inhibitor (GNS651) Wiki | 0.38 |
| drug448 | Ayurveda Wiki | 0.27 |
| drug4240 | T3011 Wiki | 0.27 |
| drug1238 | DWRX2003 Wiki | 0.22 |
| drug1640 | Famotidine Wiki | 0.17 |
| drug4112 | Standard of care Wiki | 0.07 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012509 | Sarcoma NIH | 0.38 |
| D012878 | Skin Neoplasms NIH | 0.38 |
| D009373 | Neoplasms, Germ Cell and Embryonal NIH | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012983 | Soft Tissue Neoplasms NIH | 0.38 |
| D016491 | Peripheral Vascular Diseases NIH | 0.22 |
| D008175 | Lung Neoplasms NIH | 0.19 |
| D008103 | Liver Cirrhosis, NIH | 0.19 |
| D058729 | Peripheral Arterial Disease NIH | 0.19 |
| D014652 | Vascular Diseases NIH | 0.19 |
| D009369 | Neoplasms, NIH | 0.17 |
| D007676 | Kidney Failure, Chronic NIH | 0.15 |
| D051437 | Renal Insufficiency, NIH | 0.13 |
| D017563 | Lung Diseases, Interstitial NIH | 0.10 |
| D002908 | Chronic Disease NIH | 0.10 |
| D006333 | Heart Failure NIH | 0.09 |
| D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.09 |
| D008171 | Lung Diseases, NIH | 0.07 |
| D013577 | Syndrome NIH | 0.03 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.03 |
| D055371 | Acute Lung Injury NIH | 0.03 |
| D012128 | Respiratory Distress Syndrome, Adult NIH | 0.03 |
| D003141 | Communicable Diseases NIH | 0.03 |
| D007239 | Infection NIH | 0.02 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0008069 | Neoplasm of the skin HPO | 0.38 |
| HP:0100242 | Sarcoma HPO | 0.38 |
| HP:0002898 | Embryonal neoplasm HPO | 0.38 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0100526 | Neoplasm of the lung HPO | 0.19 |
| HP:0001395 | Hepatic fibrosis HPO | 0.19 |
| HP:0002664 | Neoplasm HPO | 0.17 |
| HP:0004950 | Peripheral arterial stenosis HPO | 0.14 |
| HP:0000083 | Renal insufficiency HPO | 0.13 |
| HP:0006515 | Interstitial pneumonitis HPO | 0.10 |
| HP:0001635 | Congestive heart failure HPO | 0.09 |
| HP:0006510 | Chronic pulmonary obstruction HPO | 0.09 |
| HP:0002088 | Abnormal lung morphology HPO | 0.07 |
Navigate: Correlations HPO
There are 7 clinical trials
GNX-001 is an open-label, phase 1, multicenter, dose-escalation and expansion study of GNX102 infused every 21 days. Approximately 30 patients may be enrolled in the dose escalation portion of this study. Once the MTD or recommended phase 2 dose (RP2D) has been identified, up to 15 additional patients may be enrolled in one or two expansion cohort(s) at one or two dose levels recommended by the Safety Review Committee) to confirm the safety profile of the RP2D and provide additional information on anti-tumor activity. Patients with adeno- or epithelial-cancers that have a likelihood of GNX102 targeted antigen expression based on previous studies, including colorectal, hepatocellular, non-small cell lung, gastric, breast, pancreatic, cutaneous, acral, or mucosal melanoma, esophageal, prostate, and epithelial uterine cancers, can be screened for enrollment in the study.
Description: If ≤ 1 of 6 patients has a dose limiting toxicity (DLT) after all previous dose testing the dose will be declared the Maximum Tolerable Dose (MTD).
Measure: maximum tolerated dose (MTD) Time: Through study completion, an average of 2 yearsDescription: To evaluate antitumor activity of GNX102 by objective radiographic assessment
Measure: Antitumor activity of GNX102 Time: Through study completion, an average of 2 yearsDescription: To determine the AUC Area under the concentration curve of GNX102
Measure: AUC: Area under the concentration curve of GNX102 (μg × h/mL) Time: Through study completion, an average of 2 yearsDescription: To determine the pharmacokinetics (PK) of GNX102
Measure: Cmax: Maximum plasma concentration of GNX102 (μg) Time: Through study completion, an average of 2 yearsDescription: To determine the pharmacokinetics (PK) of GNX102
Measure: Tmax: Time to maximum plasma concentration of GNX102 (minutes) Time: Through study completion, an average of 2 yearsDescription: To determine the pharmacokinetics (PK) of GNX102
Measure: t1/2: Terminal phase half-life of GNX102 (minutes) Time: Through study completion, an average of 2 yearsDescription: To determine the pharmacokinetics (PK) of GNX102
Measure: CL: Clearance of GNX102 (L/hr) Time: Through study completion, an average of 2 yearsDescription: To determine the pharmacokinetics (PK) of GNX102
Measure: Vz: Apparent volume of distribution in the terminal phase of GNX102 (L) Time: Through study completion, an average of 2 yearsDescription: Dose-limiting AEs and toxicities will be used to establish the MTD and the recommended dose for phase 2 studies (RP2D)
Measure: Number of adverse events (AEs) and number of toxicities Time: Through study completion, an average of 2 yearsDescription: To explore tumor expression of GNX102 targeted antigens as a biomarker to predict toxicity or response to GNX102
Measure: Exploratory Outcome: GNX102 targeted antigens (counts) Time: Through study completion, an average of 2 yearsDescription: To explore serum LeB / LeY antigen levels as a potential biomarker to predict toxicity or response to GNX102
Measure: Exploratory Outcome: Serum LeB / LeY antigen levels (counts) Time: Through study completion, an average of 2 yearsDescription: To explore biomarkers related to cancer type to predict toxicity or response to GNX102
Measure: Exploratory Outcome: Serum tumor-specific antigen levels (counts) Time: Through study completion, an average of 2 yearsDescription: To evaluate the development of anti-drug antibody (ADA) to GNX102
Measure: Exploratory Outcome: Anti-drug antibody (ADA) to GNX102 (counts) Time: Through study completion, an average of 2 yearsThe objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.
Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.
Measure: EHR documentation of Goals of Care discussions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU admissions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/Hospital use: Hospital length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: Hospital Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: ICU Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.
Measure: Intensity of care: Healthcare costs Time: 1 and 3 months after randomizationDescription: From Washington State death certificates.
Measure: All-cause mortality at 1 year (safety outcome) Time: 1 year after randomizationDescription: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.
Measure: Key Implementation Factors Time: 3 months after randomizationA prospective, controlled, randomized, multicenter study whose goal is to compare the efficacy of an autophagy inhibitor (GNS561), an anti-NKG2A (monalizumab) and an anti-C5aR (avdoralimab) versus standard of care in patients with advanced or metastatic cancer who have Sars-CoV-2 infection not eligible to a resuscitation unit. According to their severity level at the time of enrolment, eligible patients will be randomized into 2 different cohorts: - COHORT 1 (mild symptoms or asymptomatic): GNS561 vs anti-NKG2A vs standard of care (randomization ratio 1:1:1). - COHORT 2 (moderate/severe symptoms): anti-C5aR vs standard of care (randomization ratio 1:1).
Description: 28-day survival rate, defined by the proportion of patients still alive 28 days after randomization. If vital status at 28 days post randomisation is not available due to early transfer in an external resuscitation unit, patients will be considered as failure at the date of the transfer. Comparison of each experimental arm (GNS561 then monalizumab for cohort1 and avdoralimab for cohort2) to control arm will be performed using a Fisher exact test.
Measure: 28-day survival rate Time: 28 days from randomizationDescription: Time to clinical improvement defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale (WHO-ISARIC) or live discharge from the hospital, whichever comes first.
Measure: Time to clinical improvement Time: 28 days from randomizationDescription: Clinical status will be assessed using a 7-point ordinal scale : Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death.
Measure: Clinical status Time: Day 7, Day 14, Day 28Description: The NEWS2 score (National Early Warning Score) allocates a score based on six physiological parameters (respiratory rate / oxygen saturation / systolic blood pressure / heart rate / consciousness / temperature). It Determines the degree of illness of a patient and prompts critical care intervention. The total possible score ranges from 0 to 21. The higher the score, the greater the clinical risk. A total score close to 0 corresponds to a low risk and a total score higher than 7 corresponds to a high risk.
Measure: Clinical status Time: Day 7, Day 14, Day 28Description: Mean change in clinical status from baseline will be assessed by using a 7-point ordinal scale.
Measure: Mean change in the ranking on the ordinal scale from baseline to D7, D14 and D28 Time: Day 7, Day 14, Day 28Description: Mean change in clinical status from baseline will be assessed by using the NEWS2 score (National Early Warning Score). The NEWS2 score (National Early Warning Score) allocates a score based on six physiological parameters (respiratory rate / oxygen saturation / systolic blood pressure / heart rate / consciousness / temperature). It Determines the degree of illness of a patient and prompts critical care intervention. The total possible score ranges from 0 to 21. The higher the score, the greater the clinical risk. A total score close to 0 corresponds to a low risk and a total score higher than 7 corresponds to a high risk.
Measure: Mean change in the ranking of the NEWS2 score from baseline to D7, D14 and D28 Time: Day 7, Day 14, Day 28Description: Overall survival will be defined by the time from date of randomization until date of death, regardless of the cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive.
Measure: Overall survival Time: 3 months (i.e. at the time of last patient last visit)Description: The length of stay in Intensive Care Unit (from the date of admission in the Unit to the date of discharge).
Measure: Length of stay in Intensive Care Unit Time: 3 months (i.e. at the time of last patient last visit)Description: The duration of mechanical ventilation or high flow oxygen devices (from the date of intubation to the stop date of mechanical ventilation or high flow oxygen)
Measure: Duration of mechanical ventilation or high flow oxygen devices Time: 3 months (i.e. at the time of last patient last visit)Description: The duration of hospitalization (from the date of hospitalization to the date of definitive discharge for live patients)
Measure: Duration of hospitalization Time: 3 months (i.e. at the time of last patient last visit)Description: Changes from baseline in neutrophils count (G/L)
Measure: Biological parameters Time: 3 months (i.e. at the time of last patient last visit)Description: Treatment-Emergent Adverse Events, Serious Adverse Events, Suspected Unexpected Serious Adverse Reactions, New Safety Issues described using the NCI-CTC AE classification v5. Number of participants with a discontinuation or temporary suspension of study drugs (for any reason).
Measure: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 Time: 3 months (i.e. at the time of last patient last visit)Description: Incremental Cost-Effectiveness Ratios (ICERs) expressed in cost per Life Year Gained.
Measure: Cost-Effectiveness Analyses (CEA) Time: 3 months (i.e. at the time of last patient last visit)Description: Changes from baseline in lymphocytes count (G/L)
Measure: Biological parameters Time: 3 months (i.e. at the the time of last patient last visit)Description: Changes from baseline in platelets count (G/L)
Measure: Biological parameters Time: 3 months (i.e. at the the time of last patient last visit)Description: Changes from baseline in hemoglobin count (g/dL)
Measure: Biological parameters Time: 3 months (i.e. at the the time of last patient last visit)Description: Changes from baseline in CRP count (mg/L)
Measure: Biological parameters Time: 3 months (i.e. at the the time of last patient last visit)Description: Changes from baseline in pro-inflammatory cytokine (IL6)
Measure: Biological parameters Time: 3 months (i.e. at the the time of last patient last visit)A phase 1, open-label, first-in-human study of T3011 monotherapy to evaluate the safety and tolerability of T3011 in patients with advanced cancers with cutaneous or subcutaneous tumor deposits who have progressed while receiving standard of care therapy or who will not benefit from such therapy.
Description: Number of participants in dose escalating arm with dose limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.
Measure: Safety and tolerability of T3011 in dose escalating administration in patients with advanced cutaneous or subcutaneous malignancies Time: From first dose of T3011 (Week 1 Day 1) until 60 days after the last T3011 injection (up to 2 years)Description: Number of participants in dose expansion arm with treatment-emergent adverse events (TEAEs), and/or changes in clinical laboratory abnormalities.
Measure: Safety and tolerability of T3011 in dose expansion administration in patients with advanced cutaneous or subcutaneous malignancies Time: From first dose of T3011 (Week 1 Day 1) until 60 days after the last T3011 injection (up to 2 years)Description: To evaluate the virus shedding following intratumoral injection
Measure: Presence and frequency of T3011 in serum, saliva, urine, and injection site/dressing Time: Up to 24 monthsDescription: To evaluate IL-12 and anti-PD-1 antibody expression of T3011 post intervention.
Measure: Quantitative measurements of serum IL-12 and anti-PD-1 antibody concentration. Time: Up to 24 monthsDescription: To evaluate the immunogenicity of anti-PD-1 antibody expressed by T3011 post intervention.
Measure: Presence of neutralizing antibodies of anti-PD-1 antibody for antidrug antibodies (ADAs) development Time: Up to 24 monthsDescription: To evaluate the immunogenicity of T3011 viral vector post intervention.
Measure: Presence of anti-herpes simplex virus type 1 (HSV-1) antibody compared to baseline Time: Up to 24 monthsDescription: ORR is defined as the proportion of participants who have a partial response (PR) or complete response (CR) to intervention, based on assessments per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
Measure: Overall response rate (ORR) Time: Up to 24 monthsDescription: DCR is defined as the percentage of participants who have achieved CR, PR, or stable disease (SD) based on assessments per RECIST 1.1.
Measure: Disease control rate (DCR) Time: Up to 24 monthsDescription: DOR is defined as the time from the first met CR or PR until disease progression or death due to any cause, whichever occurs first.
Measure: Duration of response (DOR). Time: Up to 24 monthsDescription: DR is defined as objective response (CR or PR) according to RECIST 1.1, with a duration of at least 6 months.
Measure: Durable response (DR) Time: Up to 24 monthsDescription: To evaluate the progression free survival (PFS) and overall survival (OS) of participants.
Measure: Survival (assessment per RECIST 1.1 and immune-modified RECIST (imRECIST)). Time: Up to 24 monthsStudy conducted on hospitalized patient in critical ill units in Nancy and Metz to evaluate if early corticosteroid treatment in first seven days after admission improve patients outcome in Acute Respiratory Distress Syndrome secondary to Covid-19 compared to later corticosteroid therapy or no treatment. Also comparison of acquired infection with or without corticosteroid treatment during hospitalisation.
Description: Mortality rates in ICU in each group
Measure: Mortality in ICU Time: within ICU stay, on average 15 daysDescription: mortality at day 28 after ICU admission
Measure: Mortality d28 Time: 28 daysDescription: cumulative incidence of infection acquired during ICU stay
Measure: acquired infections incidence Time: 28 daysDescription: number of treatment days with antibiotics during ICU stay
Measure: antibiotics duration Time: 28 daysDescription: number of days of treatment by mechanical ventilation during ICU stay
Measure: mechanical ventilation duration Time: 28 daysThis study will be conducted in adult participants diagnosed with advanced tumors to characterize the safety, tolerability, pharmacokinetics (PK), and activity of FS120. This is a Phase 1, multi-center, open label, multiple-dose, first in human study, designed to systematically assess safety and tolerability, and to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) for FS120 in participants with advanced tumors. Pharmacokinetics, pharmacodynamics, immunogenicity, and response will also be assessed.
Description: Safety and tolerability will be evaluated by collection of AEs, SAEs and DLTs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0.
Measure: Incidence, severity, and duration of adverse events (AEs), serious adverse events (SAEs) and dose limiting toxicities (DLTs) Time: 15 monthsDescription: Toxicity will be evaluated according to the NCI CTCAE Version 5.0.
Measure: Determination of a maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) by evaluation of DLTs Time: 28 daysBackground: About one-third to one-half of all people dying of extrathoracic malignant diseases have cancer that has spread to the lungs. Surgery may help some people. But most people with pulmonary metastases do not survive long. Researchers want to see if a combination of drugs can help. Objective: To find a safe dose of Azacytidine, when taken as a fine mist that is inhaled (aerosolized Azacytidine), together with Bintrafusp Alfa to treat cancers that have spread to the lungs. Eligibility: Adults ages 18 and older who have cancer that has spread to the lungs, cannot be cured with surgery, and has not responded to standard treatments. Design: Participants will get Azacytidine by breathing treatments once a day for 3 days each week, for 3 weeks. The 3-week period is 1 cycle. Each course of treatment is 3 cycles. Once per cycle, participants will get Bintrafusp Alfa via IV. An IV is a small tube that is put into an arm vein. Participants will keep a diary of any side effects. Participants can take the study drugs for as long as they can continue treatment. Participants will have medical histories and physical exams. They will give blood, urine, and lung lining fluid samples. Tumor samples will be taken via bronchoscopy. They will have lung function tests. Participants will have an imaging scan that shows how spray particles move in their airway when they inhale. They will have tumor imaging scans of the chest and brain. Participants will have a follow-up visit 30 days after they stop treatment.
Description: DLTs at each Phase I dose level will be reported. Pharmacokinetic analysis will be conducted using non-compartmental methods. All patients will be evaluable for toxicity from the time of their first treatment with AZA/ Bintrafusp alfa. Dose limiting toxicities will be assessed during the first 3 cycles of AZA/ Bintrafusp alfa therapy. Patients who have measurable disease present at baseline, have received at least 9 weeks of AZA/Bintrafusp alfa therapy (three cycles), and have had their disease re-evaluated will be considered evaluable for response.
Measure: Phase I: Determine pharmacokinetics, toxicities, maximum tolerated dose and recommended Phase 2 dose (RP2D) of aerosolized AZA in patients receiving IV Bintrafusp alfa for unresectable pulmonary metastases Time: baseline, first treatment, end of each courseDescription: Patients who have measurable disease present at baseline, have received at least 9 weeks of AZA/Bintrafusp alfa therapy (three cycles), and have had their disease re-evaluated will be considered evaluable for response provided.
Measure: Phase II: Determine frequency of intrathoracic objective clinical response in patients with unresectable pulmonary metastases following administration of aerosolized AZA at the RP2D and IV Bintrafusp alfa Time: baseline, end of each courseAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports